Skip to main content
. 2016 Nov 18;92(1):50–55. doi: 10.1002/ajh.24582

Figure 1.

Figure 1

Significant differences in cumulative incidence rates (CIR) from multiple myeloma (MM)‐specific death were seen among beta‐blockers (BB) intake groups. The patients who took only BB had the lowest 5‐year CIR (23.5%), followed by those taking both BB and other cardiac drugs (31.9%), no cardiac drugs use (41.3%), and other non‐BB cardiac medications (49.9%).